Biochemical assessment of metabolic associated fatty liver disease
Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%)...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2021-03-01
|
| Series: | Advances in Laboratory Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/almed-2021-0009 |
| _version_ | 1827916277487763456 |
|---|---|
| author | Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel |
| author_facet | Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel |
| author_sort | Guerra-Ruiz Armando R. |
| collection | DOAJ |
| description | Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients. |
| first_indexed | 2024-03-13T03:12:51Z |
| format | Article |
| id | doaj.art-4e33d0f9576b45d187bf542aad328304 |
| institution | Directory Open Access Journal |
| issn | 2628-491X |
| language | English |
| last_indexed | 2024-03-13T03:12:51Z |
| publishDate | 2021-03-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Advances in Laboratory Medicine |
| spelling | doaj.art-4e33d0f9576b45d187bf542aad3283042023-06-26T10:46:03ZengDe GruyterAdvances in Laboratory Medicine2628-491X2021-03-012219920810.1515/almed-2021-0009Biochemical assessment of metabolic associated fatty liver diseaseGuerra-Ruiz Armando R.0Casals Gregori1Iruzubieta Paula2Lalana Marta3Leis Alba4López Rosa María5Crespo Javier6Morales-Ruiz Manuel7Commission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainCommission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainSpanish Society of Digestive Pathology (SEPD), Madrid, SpainCommission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainCommission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainCommission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainSpanish Society of Digestive Pathology (SEPD), Madrid, SpainCommission on Biochemistry of Liver Disease, Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, SpainMetabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.https://doi.org/10.1515/almed-2021-0009hepatic steatosisliver fibrosismetabolic-associated fatty liver diseaseserum markerssteatohepatitis |
| spellingShingle | Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel Biochemical assessment of metabolic associated fatty liver disease Advances in Laboratory Medicine hepatic steatosis liver fibrosis metabolic-associated fatty liver disease serum markers steatohepatitis |
| title | Biochemical assessment of metabolic associated fatty liver disease |
| title_full | Biochemical assessment of metabolic associated fatty liver disease |
| title_fullStr | Biochemical assessment of metabolic associated fatty liver disease |
| title_full_unstemmed | Biochemical assessment of metabolic associated fatty liver disease |
| title_short | Biochemical assessment of metabolic associated fatty liver disease |
| title_sort | biochemical assessment of metabolic associated fatty liver disease |
| topic | hepatic steatosis liver fibrosis metabolic-associated fatty liver disease serum markers steatohepatitis |
| url | https://doi.org/10.1515/almed-2021-0009 |
| work_keys_str_mv | AT guerraruizarmandor biochemicalassessmentofmetabolicassociatedfattyliverdisease AT casalsgregori biochemicalassessmentofmetabolicassociatedfattyliverdisease AT iruzubietapaula biochemicalassessmentofmetabolicassociatedfattyliverdisease AT lalanamarta biochemicalassessmentofmetabolicassociatedfattyliverdisease AT leisalba biochemicalassessmentofmetabolicassociatedfattyliverdisease AT lopezrosamaria biochemicalassessmentofmetabolicassociatedfattyliverdisease AT crespojavier biochemicalassessmentofmetabolicassociatedfattyliverdisease AT moralesruizmanuel biochemicalassessmentofmetabolicassociatedfattyliverdisease |